Immuno-oncology upset in bladder cancer

Nature Reviews Drug Discovery 16, 375 (2017). doi:10.1038/nrd.2017.108 Author: Asher Mullard Roche and Genentech's checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated approval to the anti-programmed cell death protein 1 ligand 1 (PDL1) antibody for this indication in 2016
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research